1.由于计划调整吗替麦考酚酯胶囊250mg（USP)和吗替麦考酚酯片5

1. Since the adjustment program mycophenolate mofetil capsule 250mg (USP) and mycophenolate mofetil tablets 500mg (USP) determined production, packaging materials tag failed storage planned orders. <br>2 batch record labels and update registration information reported to belong to the annual report to be determined according to the production plan, now mycophenolate mofetil capsules 250mg (USP) and it confirmed MMF tablets 500mg (USP) production. <br>3. Since mycophenolate mofetil capsule 250mg (USP) and mycophenolate mofetil tablets 500mg (USP) standards old and new label is detected by mass held constant. "

1. Due to the planned adjustment for the McCorco phenolester capsule 250mg (USP) and for McCorcophenol tablets 500mg (USP) production pending, the package label failed to place an order into storage as originally planned.<br>2 Label and batch records registration information update report belongs to the annual report to be determined according to the production plan, now for McCorveyeste capsule 250mg (USP) and for McCo-phenol tablets 500mg (USP) production pending.<br>3. Due to the 250mg (USP) of the McCo-phenol capsule and the new and old label quality standard stoic test items for McCorcophenol tablets 500mg (USP). "

1. Due to the adjustment of the production plan of 250mg (USP) and 500mg (USP) of mycophenolate mofetil capsules, the label of packaging materials failed to place an order for warehousing according to the original plan.<br>2. The updating and reporting of the label and batch record registration data belong to the annual report, which can only be determined according to the production plan. Now, the production of 250mg (USP) of mycophenolate capsule and 500mg (USP) of mycophenolate tablet is to be determined.<br>3. The test items of the new and old label quality standards of metoclopramide 250mg (USP) and metoclopramide 500mg (USP) were unchanged. "<br>